alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          MAR-31-2000
<PERIOD-END>                               DEC-31-1999
<CASH>                                          28,580
<SECURITIES>                                         0
<RECEIVABLES>                                  224,400
<ALLOWANCES>                                         0
<INVENTORY>                                    130,225
<CURRENT-ASSETS>                               423,242
<PP&E>                                         422,264
<DEPRECIATION>                               (134,742)
<TOTAL-ASSETS>                                 919,946
<CURRENT-LIABILITIES>                          150,935
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       204,256
<OTHER-SE>                                     247,023
<TOTAL-LIABILITY-AND-EQUITY>                   919,946
<SALES>                                        570,534
<TOTAL-REVENUES>                               570,534
<CGS>                                          310,840
<TOTAL-COSTS>                                  310,840
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              11,482
<INCOME-PRETAX>                                 55,893
<INCOME-TAX>                                    21,215
<INCOME-CONTINUING>                             34,678
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    34,678
<EPS-BASIC>                                       0.51
<EPS-DILUTED>                                     0.51


</TABLE>
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.7280 Factor V Leiden DNA mutation detection systems. ( a ) *Identification.* Factor V Leiden deoxyribonucleic acid (DNA) mutation detection systems are devices that consist of different reagents and instruments which include polymerase chain reaction (PCR) primers, hybridization matrices, thermal cyclers, imagers, and software packages. The detection of the Factor V Leiden mutation aids in the diagnosis of patients with suspected thrombophilia.
( b ) *Classification.* Class II (special controls). The special control is FDA's guidance entitled “Class II Special Controls Guidance Document: Factor V Leiden DNA Mutation Detection Systems.” (See § 864.1(d) for the availability of this guidance document.)
[69 FR 12273, Mar. 16, 2004]
Editorial Note on Part 874
Editorial Note: Nomenclature changes to part 874 appear at 73 FR 35341, June 23, 2008.

§ 874.4175 Nasopharyngeal catheter. ( a ) *Identification.* A nasopharyngeal catheter is a device consisting of a bougie or filiform catheter that is intended for use in probing or dilating the eustachian tube. This generic type of device includes eustachian catheters.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 874.9.
[51 FR 40389, Nov. 6, 1986, as amended at 61 FR 1122, Jan. 16, 1996; 66 FR 38801, July 25, 2001]
§ 520.90a Ampicillin tablets. ( a ) *Specifications.* Each tablet contains ampicillin trihydrate equivalent to 50 or 100 milligrams of ampicillin.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* 5 milligrams per pound of body weight, at 8-hour intervals, 1 to 2 hours prior to feeding, to be continued 36 to 48 hours after all symptoms have subsided. If no improvement is seen within 5 days, stop treatment, reevaluate diagnosis, and change therapy.
( 2 ) *Indications for use.* Oral treatment of infections caused by susceptible organisms as follows: Upper respiratory infections, tonsillitis, and bronchitis due to *Streptococcus* spp., *Staphylococcus* spp., *Escherichia coli, Proteus mirabilis,* and *Pasteurella* spp., urinary tract infections (cystitis) due to *Streptococcus* spp., *Staphylococcus* spp., *E., coli, P. mirabilis,* and *Enterococcus* spp.; gastrointestinal infections due to *Staphylococcus* spp., *Streptococcus* spp., *Enterococcus* spp., and *E. coli.* ; infections associated with abscesses, lacerations, and wounds caused by *Staphylococcus* spp., and *Streptococcus* spp.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[57 FR 37321, Aug. 18, 1992, as amended at 60 FR 55659, Nov. 2, 1995; 79 FR 28818, May 20, 2014. Redesignated at 85 FR 18118, Apr. 1, 2020]
|FORM 6 - K
|----------



|SECURITIES AND EXCHANGE
COMMISSION  Washington, D.C. 20549
|----------------------------------------------------------



|Report of Foreign Private
Issuer  Pursuant to Rule 13a - 16 or 15d - 16 of  the Securities Exchange Act of 1934
|---------------------------------------------------------------------------------------------------------------



|As of March 7, 2003
|-------------------



|TENARIS, S.A.  (Translation of
Registrants name into English)
|--------------------------------------------------------------



|TENARIS, S.A.  23 Avenue
Monterey  2086 Luxembourg  (Address of principal executive offices)
|--------------------------------------------------------------------------------------------



|Indicate by check mark whether
the registrant files or will file  annual reports under cover Form 20-F or 40-F.
|---------------------------------------------------------------------------------------------------------------



|Form 20-F |X| Form 40-F |_|
|---------------------------



|Indicate by check
mark whether the registrant by furnishing the  information contained in this Form is also
thereby furnishing the information to  the Commission pursuant to Rule 12G3-2(b) under
the Securities Exchange Act of  1934.
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|Yes  |_|  No  |X|
|-----------------



|If Yes is marked, indicate below
      the file number assigned to the registrant in connection with 
      Rule 12g3-2(b): 82-_______.
|-----------------------------------------------------------------------------------------------------------------------------------------



| |  | 
| |  | 



---





|The attached material is being furnished to the
Securities and Exchange  Commission pursuant to Rule 13a-16 and Form 6-K under the
Securities Exchange  Act of 1934, as amended. This report contains Tenariss press
release announcing  its 2002 Annual Results
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|SIGNATURE
|---------



|Pursuant to the requirements of the Securities
Exchange Act of 1934, the  Registrant has duly caused this report to be signed on its
behalf by the  undersigned, thereunto duly authorized.
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|Date: March 7, 2003
|-------------------



|Tenaris, S.A.
|-------------



|By: /s/ Cecilia Bilesio
      Cecilia Bilesio
      Corporate Secretary
|-----------------------------------------------------------------------



| |  | 
| |  | 



---
Promissory Note, Deed of Trust and Security Agreement


  EXHIBIT 10.02
  Plaza Hotel and Casino
 One Main Street
 P.O. Box 760
 Las Vegas, Nevada
89101
  NOTE SECURED BY DEED OF TRUST

	  January 21, 2000
 	  Las Vegas, Nevada
 

  For value received, the undersigned promises to pay EXBER, INC., or order, at Las
Vegas, Nevada the sum of twenty nine million four hundred thousand ($29,400,000.00) with interest from the date on unpaid principal at the Prime Interest Rate as published in the Wall Street Journal as of the 20th of each month, not to
exceed 12.0%.  Monthly installments of interest are due and payable on the first day of each month beginning on February 1, 2000, for a period of 60 months at which time the entire remaining principal balance together with accrued interest
shall be due and payable.
  Each payment shall be credited first on accrued interest, remainder on principal; and interest shall thereupon cease upon the principal so credited.  Should default
be made in payment of any installment of interest, the whole sum of interest and principal shall become immediately due at the option of the holder hereof.  Principal and interest payable in lawful money of the United States.  Should the
payee or his assigns be required to engage an attorney to enforce any provision of this note or Deed of Trust securing same, or in any proceeding brought by the undersigned promises to pay said sums as the court may fix as attorneys fees.


	  
 	  UNION PLAZA HOTEL AND CASINO, INC.
 
	  
 	  
 
	  
 	  
 
	  
 	 By:
 	  /s/  JOHN D. GAUGHAN
 
	   
 	   
 	 
 
	   
 	   
 	  Its President
 
	  
 	  
 	  
 
	  
 	  Attest:  
 	  /s/  DON DOBSON
 
	   
 	   
 	 
 
	  
 	  
 	  Its Secretary
Exihibit
14.4

Statement Regarding Consent of Arthur Andersen and Arthur
Andersen Sp. z.o.o.

The consolidated financial statements for
2001 and 2000 of Virgin Mobile Telecoms Limited ("Virgin
Mobile") and Polska Telefonia Cyfrowa Sp. z o.o.
("PTC") appearing in our annual report on
Form 20-F for the year ended December 31, 2003, as amended, have been
audited by Arthur Andersen and Arthur  Andersen Sp. z o.o.

We have not been able to obtain, after reasonable efforts, the
written consent of Arthur Andersen or Arthur Andersen Sp. z o.o., as
required by Section 7 of the Securities Act for incorporation by
reference of their respective reports on the consolidated financial
statements of Virgin Mobile and PTC for 2001. Rule 437a of the
Securities Act permits us to include these reports on the financial
statements incorporated by reference herein without the consent of
Arthur Andersen and Arthur Andersen Sp. z o.o. Because Arthur Andersen
and Arthur Andersen Sp. z o.o. have not consented to the incorporation
by reference of their respective reports herein, your ability to
recover for claims against Arthur Andersen and Arthur Andersen Sp. z
o.o. may be limited. In particular, you will not be able to recover
against Arthur Andersen or Arthur Andersen Sp. z o.o., under Section
11(a)(4) of the Securities Act for any untrue material fact contained
in the financial statements audited by Arthur Andersen and Arthur
Andersen Sp. z o.o., or any omission to state a material fact required
to be stated therein.

---
[Federal Register Volume 75, Number 43 (Friday, March 5, 2010)]
[Notices]
[Page 10330]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-4669]



[[Page 10330]]

-----------------------------------------------------------------------

SMALL BUSINESS ADMINISTRATION

[Disaster Declaration <greek-i> 12051 and <greek-i> 12052]


Oklahoma Disaster <greek-i> OK-00034

AGENCY: U.S. Small Business Administration

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a Notice of the Presidential declaration of a major 
disaster for Public Assistance Only for the State of Oklahoma (FEMA-
1876-DR), dated 02/25/2010.
    Incident: Severe Winter Storm.
    Incident Period: 12/24/2009 through 12/25/2009.

DATES: Effective Date: 02/25/2010.
    Physical Loan Application Deadline Date: 04/26/2010.
    Economic Injury (EIDL) Loan Application Deadline Date: 11/25/2010.

ADDRESSES: Submit completed loan applications to: U.S. Small Business 
Administration, Processing and Disbursement Center, 14925 Kingsport 
Road, Fort Worth, TX 76155.

FOR FURTHER INFORMATION CONTACT: A. Escobar, Office of Disaster 
Assistance, U.S. Small Business Administration, 409 3rd Street, SW., 
Suite 6050, Washington, DC 20416.

SUPPLEMENTARY INFORMATION: Notice is hereby given that as a result of 
the President's major disaster declaration on 02/25/2010, Private Non-
Profit organizations that provide essential services of governmental 
nature may file disaster loan applications at the address listed above 
or other locally announced locations.
    The following areas have been determined to be adversely affected 
by the disaster:

Primary Counties: Canadian, Cleveland, Comanche, Cotton, Craig, 
Delaware, Garvin, Grady, Hughes, Jackson, Jefferson, Kay, Lincoln, 
Love, Mcclain, Muskogee, Noble, Nowata, Okfuskee, Okmulgee, Ottawa, 
Payne, Pontotoc, Pottawatomie, Rogers, Sequoyah, Stephens, Tillman, 
Tulsa.

    The Interest Rates are:

------------------------------------------------------------------------
                                                                 Percent
------------------------------------------------------------------------
For Physical Damage:
  Non-Profit Organizations With Credit Available Elsewhere....     3.625
  Non-Profit Organizations Without Credit Available Elsewhere.     3.000
For Economic Injury:
  Non-Profit Organizations Without Credit Available Elsewhere.     3.000
------------------------------------------------------------------------

    The number assigned to this disaster for physical damage is 12051B 
and for economic injury is 12052B.

(Catalog of Federal Domestic Assistance Numbers 59002 and 59008)

James E. Rivera,
Associate Administrator for Disaster Assistance.
[FR Doc. 2010-4669 Filed 3-4-10; 8:45 am]
BILLING CODE 8025-01-P
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1645 Urinary protein or albumin (nonquantitative) test system. ( a ) *Identification.* A urinary protein or albumin (nonquantitative) test system is a device intended to identify proteins or albumin in urine. Identification of urinary protein or albumin (nonquantitative) is used in the diagnosis and treatment of disease conditions such as renal or heart diseases or thyroid disorders, which are characterized by proteinuria or albuminuria.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2308, Jan. 14, 2000]
P. 1


# RCRA Box 1883 Prepped byOllie Stewart



### Document

Number: 

# 103 ) ll-B-26 5 Docket Number: 

# A-90-1 9

Printed 12/3/200810:42:17

AM Sheet 103 of 171>V

MEMORANDU M— 

## A-90-1 9 ll-B-265 P. 2

DATE : February14 , 199 2 TO : Projec t Fil e FROM : Bennet t King SUBJECT : Classificatio no f Organi c HAP' s 

# lijriiiLoX
. k MAI RDOCKE T 

# J Th e CleanAi r Ac t Amendment s lis t o f 18 9 HAP' s include da numbe r o f compound classes . Fo r purpose s o f th e background informatio ndocument , Volume IA , Chapte r 3 , Sourc e Category Descriptio nan

d SOCM I Characterization , al l chemical s o r classe s o f compound s wer e identifie da s inorganic , organic , o r both ; 'both ' onl yapplie s t o classe s o f compounds . Using Lanae' s Handboo k o f Chemistry , compound s representing eac hclas s o f compound s wer e looke d up i n th e organi c an

d inorgani c section s o f th e book . Attachmen t 1 show s th e pag e number s i n Lange' s wher e representative s o f eac h compound clas s wer e found . Cok e ove nemission s d o no t appea r i n Lange' s o r i n simila r readil yavailabl e references . However , sinc e cok e ove nemission s wer e no t considere d fo r th e HONimpac t analysis , thei r classificatio na s organic , inorganic , o r bot hwa s no t pursue d further . Fo r completenes s sake , engineering judgmen t wa s use d an d Tabl e 3- 1 i n Chapte r 3 indicate s tha t cok e ove nemission s ar e bot horgani c an

d inorganic . cc : Projec t Fil e 6. 1 (M . Haley ) Rut hMead , Radia n Juli e Ann e Probert , Radia n Ja nMeyer , EPA/SD B

Lange , N.A . 1979 , Lange' s Handboo k o f Chemistry , 12t h edition . J.A . Dean , ed . McGrawP. 3

ATTACHMENT TiPAG E NUMBER S I NLANGE' S FOREXAMPL E INORGANI C AN D ORGANI C COMPOUND S Chemica l Compound s Inorgani c Pag e # Organi c Pag e # Antimon ycompound s 4-2 3 7-8 8 Arseni c compound s 4-2 4 7-8 8 Berylliu

m compound s 4-2 8 7-10 2 Cadmiu m compound s 4-3 1 7-12 0 Chromiu mcompound s 4-4 2 Cobal t compound s 4-4 4 Cyanid e compound s 4-5 0 7-14 0 Lead compound s 4-6 6 7-26 2 Manganes e compound s 4-7 1 Mercurycompound s 4-7 6 7-26 6 Nicke l compound s 4-8 1 Seleniu mcompound s 4-10 4 7-34 8
**Exhibit 32.1**

 

**CERTIFICATIONPURSUANT TO**

**SECTION 1350,CHAPTER 63 OF TITLE 18, UNITED STATES CODE,**

**ASADOPTED PURSUANT TO**

**SECTION 906OF THE SARBANES-OXLEY ACT OF 2002**

 

Pursuant to Section 1350,Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906of the Sarbanes-Oxley Act of 2002, the undersigned, as Chief Executive Officerof The Timberland Company (the “Company”), does hereby certify that to theundersigned’s knowledge:

 

1.             The Company’s Quarterly Report on Form 10-Q for theperiod ending July 1, 2005 fully complies with the requirements of Section 13(a) or15(d) of the Securities Exchange Act of 1934; and

 

2.             The information contained in the Company’s QuarterlyReport on Form 10-Q for the period ending July 1, 2005 fairly presents,in all material respects, the financial condition and results of operations ofthe Company.

 

 
|   /S/ JEFFREY  B. SWARTZ |   |
|------------------------------------|--------|
| Jeffrey B. Swartz                  |
| Chief Executive Officer            |

 

Date: August 10,2005

 

The foregoingcertification is being furnished solely pursuant to Section 906 of theSarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350,Chapter 63 of Title 18, United States Code) and is not being filed as part ofthe Form 10-Q or as a separate disclosure document.

 

A signed original of thiswritten statement, required by Section 906, has been provided to TheTimberland Company and will be retained by The Timberland Company and furnishedto the Securities and Exchange Commission or its staff upon request.

 

1

----
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.1800 Rhinoanemometer. ( a ) *Identification.* A rhinoanemometer is a device used to quantify the amount of nasal congestion by measuring the airflow through, and differential pressure across, a patient's nasal passages.
( b ) *Classification.* Class II (performance standards).
§ 74.1317 D&C Red No. 17. ( a ) *Identity.* ( 1 ) The color additive D&C Red No. 17 is principally 1-[[4-(phenylazo)phenyl]azo]-2-naphthalenol.
( 2 ) Color additive mixtures for drug use made with D&C Red No. 17 may contain only those diluents that are suitable and that are listed in part 73 of this chapter as safe for use in color additive mixtures for coloring externally applied drugs.
( b ) *Specifications.* D&C Red No. 17 shall conform to the following specifications and shall be free from impurities, other than those named, to the extent that such other impurities may be avoided by good manufacturing practice: Volatile matter (at 135 °C), not more than 5 percent. Matter insoluble in both toluene and water (color additive mixed in toluene and the resultant residue isolated and mixed with water to obtain the matter insoluble in both toluene and water), not more than 0.5 percent. Chlorides and sulfates (calculated as sodium salts), not more than 3 percent. Aniline, not more than 0.2 percent. 4-Aminoazobenzene, not more than 0.1 percent. 2-Naphthol, not more than 0.2 percent. 1-(Phenylazo)-2-naphthol, not more than 3 percent. 1-[[2-(phenylazo) phenyl]azo]-2-naphthalenol, not more than 2 percent. Lead (as Pb), not more than 20 parts per million. Arsenic (as As), not more than 3 parts per million. Mercury (as Hg), not more than 1 part per million. Total color, not less than 90 percent.
( c ) *Uses and restrictions.* D&C Red No. 17 may be safely used in externally applied drugs in amounts consistent with good manufacturing practice.
( d ) *Labeling.* The label of the color additive and any mixtures prepared therefrom intended solely or in part for coloring purposes shall conform to the requirements of § 70.25 of this chapter.
( e ) *Certification.* All batches of D&C Red No. 17 shall be certified in accordance with regulations in part 80 of this chapter.
[42 FR 15654, Mar. 22, 1977, as amended at 42 FR 27225, May 27, 1977]
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          JAN-31-2000
<PERIOD-START>                             FEB-01-2000
<PERIOD-END>                               JUL-31-2000
<CASH>                                       1,745,000
<SECURITIES>                                         0
<RECEIVABLES>                                  992,000
<ALLOWANCES>                                    20,000
<INVENTORY>                                    335,000
<CURRENT-ASSETS>                             3,161,000
<PP&E>                                       1,446,000
<DEPRECIATION>                               1,098,000
<TOTAL-ASSETS>                               4,746,000
<CURRENT-LIABILITIES>                          697,000
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                     7,192,000
<OTHER-SE>                                 (3,143,000)
<TOTAL-LIABILITY-AND-EQUITY>                 4,746,000
<SALES>                                      4,237,000
<TOTAL-REVENUES>                             4,280,000
<CGS>                                        2,359,000
<TOTAL-COSTS>                                3,106,000
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                14,000
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                693,000
<INCOME-TAX>                                    10,000
<INCOME-CONTINUING>                            683,000
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   683,000
<EPS-BASIC>                                        .03
<EPS-DILUTED>                                      .03


</TABLE>
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.5010 Nonabsorbable polypropylene surgical suture. ( a ) *Identification.* Nonabsorbable polypropylene surgical suture is a monofilament, nonabsorbable, sterile, flexible thread prepared from long-chain polyolefin polymer known as polypropylene and is indicated for use in soft tissue approximation. The polypropylene surgical suture meets United States Pharmacopeia (U.S.P.) requirements as described in the U.S.P. Monograph for Nonabsorbable Surgical Sutures; it may be undyed or dyed with an FDA approved color additive; and the suture may be provided with or without a standard needle attached.
( b ) *Classification.* Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: Surgical Sutures; Guidance for Industry and FDA.” See § 878.1(e) for the availability of this guidance document.
[56 FR 24685, May 31, 1991, as amended at 68 FR 32984, June 3, 2003]